Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aelis Farma S.A. (AELIS.PA)
Bordeaux, FR
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.16% | +3.28% | -1.56% | -10.00% | +14.55% | +11.50% | +4.13% | -91.00% | -90.00% | -90.00% | -90.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-22.2% Q4'25: -77.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+13.0% Q4'25: +42.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-408.5% Q4'25: -124.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-397.4% Q4'25: -347.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-292.7% Q4'25: -400.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +4.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.82× Q4'25: -0.42× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
9.08M
est: 34.00M (-73.3%)
|
3.81M
est: 1.40M (+172.1%)
|
9.05M
est: 10.78M (-16.0%)
|
2.68M
est: 7.00M (-61.7%)
|
2.08M
est: 3.30M (-36.8%)
|
12.40M
12.40M – 12.40M
+275.8% YoY
|
48.80M
48.80M – 48.80M
+293.5% YoY
|
| EBITDA |
844.0K
est: -24.53M (+103.4%)
|
-16.23M
est: -1.01M (-1,506.2%)
|
-6.35M
est: -7.78M (+18.4%)
|
-8.62M
est: -5.05M (-70.6%)
|
-8.00M
est: -2.38M (-236.0%)
|
-8.95M
-8.95M – -8.95M
-275.8% YoY
|
-35.21M
-35.21M – -35.21M
-293.5% YoY
|
| EBIT |
809.0K
est: -24.69M (+103.3%)
|
-16.30M
est: -1.02M (-1,503.2%)
|
-6.52M
est: -7.83M (+16.8%)
|
-7.45M
est: -5.08M (-46.5%)
|
-8.28M
est: -2.40M (-245.6%)
|
-9.00M
-9.00M – -9.00M
-275.8% YoY
|
-35.43M
-35.43M – -35.43M
-293.5% YoY
|
| Net Income |
574.0K
|
-14.29M
est: -19.87M (+28.1%)
|
-5.08M
est: -7.29M (+30.4%)
|
-7.46M
est: -2.60M (-186.3%)
|
-6.43M
est: -6.03M (-6.7%)
|
2.33M
2.33M – 2.33M
+138.6% YoY
|
35.36M
35.36M – 35.36M
+1,417.6% YoY
|
| SGA |
562.0K
est: 14.86M (-96.2%)
|
1.67M
est: 611.7K (+173.0%)
|
1.10M
est: 5.30M (-79.3%)
|
3.36M
est: 3.44M (-2.6%)
|
1.22M
est: 1.62M (-24.8%)
|
6.10M
6.10M – 6.10M
+275.8% YoY
|
24.01M
24.01M – 24.01M
+293.5% YoY
|
| EPS |
0.06
|
-1.21
est: -1.45 (+16.6%)
|
-0.39
est: -0.53 (+26.7%)
|
-0.54
est: -0.19 (-184.2%)
|
-0.47
est: -0.44 (-6.8%)
|
0.17
0.17 – 0.17
+138.6% YoY
|
2.58
2.58 – 2.58
+1,417.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pier Vincenzo Piazza | Chief Executive Officer & Director | 458.6K | — |
| Stephanie Monlezun | Chief Operating Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AELIS.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
